Life Sciences
Earnings update: Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona
A flood of quarterly earnings for North Carolina public companies continues with Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona reporting.
The…
RESEARCH TRIANGLE PARK – A flood of quarterly earnings for North Carolina public companies continues with Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona reporting.
Here are links to their announcements:
- Vontier: https://www.businesswire.com/news/home/20230803075941/en/Vontier-Reports-Strong-Second-Quarter-2023-Results-and-Raises-Full-Year-Guidance
- AvidXchange: https://ir.avidxchange.com/news-releases/news-release-details/avidxchange-announces-second-quarter-2023-financial-results
- Fennec Pharmaceuticals: https://www.globenewswire.com/news-release/2023/08/03/2717728/0/en/Fennec-Pharmaceuticals-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
- G1 Therapeutics: https://www.globenewswire.com/news-release/2023/08/02/2716638/0/en/G1-Therapeutics-Provides-Second-Quarter-2023-Financial-Results-and-Operational-Highlights.html
- Enact: https://www.globenewswire.com/news-release/2023/08/01/2716425/0/en/Enact-Reports-Second-Quarter-2023-Results.html
- Verona Pharma: https://www.globenewswire.com/news-release/2023/08/03/2717625/0/en/Verona-Pharma-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
The post Earnings update: Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona first appeared on WRAL TechWire.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
